Heterocyclic Compounds Selective S1P1 Agonists

Solution Overview

Problem

There is a need for S1P1 agonists that are selective over S1P3 to avoid the undesirable cardiovascular effects associated with non-selective S1P receptor modulation, such as bradycardia and hypertension, while maintaining therapeutic efficacy in autoimmune and vascular diseases.

Innovation Solution

Development of heterocyclic compounds that act as selective S1P1 agonists, reducing or minimizing side effects by targeting S1P1 activity over S1P3 activity, with specific structures and processes for their synthesis and use in pharmaceutical compositions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If non-selective S1P receptor modulation is used, then immunosuppression efficacy is improved, but cardiovascular side effects (bradycardia, hypertension) worsen

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the S1P receptor family by developing compounds that selectively target only the S1P1 receptor subtype, separating the desired immunosuppressive effects from the undesired cardiovascular effects mediated by other S1P receptor subtypes (particularly S1P3). This selective agonism at S1P1 receptors on lymphocytes achieves immunosuppression without activating S1P3 receptors in the cardiovascular system, thereby resolving the contradiction between efficacy and side effects.

Inventive Principle:
Principle #1Segmentation

2Object-affected harmful factors

If S1P1 receptor selectivity is increased, then cardiovascular side effects are reduced, but therapeutic efficacy may be compromised

Engineering Contradiction:
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent optimizes the chemical structure parameters of the heterocyclic compounds (specifically the FTY720-phosphate analog structure with modifications at positions 1, 2, and 3) to achieve high selectivity for S1P1 receptors while maintaining potent agonist activity. The structural parameters are tuned to maximize binding affinity for S1P1 receptors (Ki < 10 nM) while minimizing off-target effects, thereby preserving therapeutic efficacy while reducing cardiovascular side effects.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentUS8399451B2Heterocyclic compounds
Publication Date: 2013.03.19
  • US8399451B2 patent drawing
  • US8399451B2 patent drawing
  • US8399451B2 patent drawing

AI summary

Disclosed are compounds of Formula (I)or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein:A isQ is a substituted 5-membered monocyclic heteroaryl group;W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.